AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30413379 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline group (5-fluorouracil, epirubicin, cyclophosphamide followed by paclitaxel and carboplatin)
Number of subjects: 438
Study 30413379 — intervention group
Group type: COMPARATOR
Intervention: Non-anthracycline group (paclitaxel and carboplatin)
Number of subjects: 438
Study 30413379 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline group
Number of subjects: 438
Study 30413379 — intervention group
Group type: COMPARATOR
Intervention: Non-anthracycline group
Number of subjects: 438
Study 26806732 — intervention group
Group type: EXPERIMENTAL
Intervention: Annular electrode lacrimal duct reconstruction
Number of subjects: 119
Study 26806732 — intervention group
Group type: COMPARATOR
Intervention: No annular electrode lacrimal duct reconstruction (control)
Number of subjects: 119
Study 24766973 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily (15 mg if creatinine clearance is 30‐49 mL/min)
Number of subjects: 1500
Study 24766973 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted vitamin K antagonists (VKAs; INR 2.0‐3.0)
Number of subjects: 1500
Study 24766973 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban or VKA administered for 21 to 56 days before cardioversion
Number of subjects: 1500
Study 24766973 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban or VKA administered for 6 weeks postcardioversion
Number of subjects: 1500
Study 22963001 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (pharmacologic intervention)
Number of subjects: 106
Study 19286123 — intervention group
Group type: EXPERIMENTAL
Intervention: BART intervention (8-week community-based translation)
Number of subjects: 246
Study 19286123 — intervention group
Group type: COMPARATOR
Intervention: General health education control group
Number of subjects: 246
Study 17460710 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 100
Study 17460710 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg
Number of subjects: 100
Study 17460710 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 100
Study 17460710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15366799 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 400
Study 15366799 — intervention group
Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 400
Study 11583728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg, twice daily)
Number of subjects: 32
Study 11583728 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (400 mg, twice daily)
Number of subjects: 32
Study 10741176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% mitomycin C solution
Number of subjects: 130
Study 10741176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mitomycin C)
Number of subjects: 130
Study 8016037 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion interventions at 16 sites
Number of subjects: 32
Study 8016037 — intervention group
Group type: COMPARATOR
Intervention: Sites changing from unrestrictive to restrictive policies
Number of subjects: 32
Study 8016037 — intervention group
Group type: COMPARATOR
Intervention: Restrictive smoking policies
Number of subjects: 32
Study 2807523 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10^8 organisms)
Number of subjects: 24
Study 2807523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 131976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisuccinate (steroid group)
Number of subjects: 98
Study 131976 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treatment (control group)
Number of subjects: 98
Study 30374746 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to imagine themselves in the situation of a social benefit claimant
Number of subjects: 60
Study 30374746 — intervention group
Group type: COMPARATOR
Intervention: Control group instructed to answer honestly
Number of subjects: 60
Study 28527545 — intervention group
Group type: EXPERIMENTAL
Intervention: Relief band using transcutaneous electrical nerve stimulation
Number of subjects: 54
Study 28527545 — intervention group
Group type: COMPARATOR
Intervention: Wrist band using acupressure
Number of subjects: 54
Study 26413979 — intervention group
Group type: EXPERIMENTAL
Intervention: GD Choice
Number of subjects: 68
Study 26413979 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 68
Study 23336549 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention (five weekly 90-minute group sessions)
Number of subjects: 173
Study 23336549 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 173
Study 21700924 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 42
Study 21700924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐arm intensive bimanual therapy (HABIT)
Number of subjects: 42
Study 18853558 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of monozygotic twins
Number of subjects: 0
Study 18853558 — intervention group
Group type: COMPARATOR
Intervention: Control parents (non-twin siblings)
Number of subjects: 0
Study 18853558 — intervention group
Group type: EXPERIMENTAL
Intervention: Twins' parents with inverted faces
Number of subjects: 0
Study 18853558 — intervention group
Group type: EXPERIMENTAL
Intervention: Twins' parents with familiar faces
Number of subjects: 0
Study 16625986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin 160 microg
Number of subjects: 16
Study 16625986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin 240 microg
Number of subjects: 16
Study 16625986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin 320 microg
Number of subjects: 16
Study 16625986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin (all doses)
Number of subjects: 16
Study 15598859 — intervention group
Group type: EXPERIMENTAL
Intervention: Deadline (n = 126)
Number of subjects: 246
Study 15598859 — intervention group
Group type: COMPARATOR
Intervention: No Deadline (n = 120)
Number of subjects: 246
Study 15598859 — intervention group
Group type: EXPERIMENTAL
Intervention: Deadline
Number of subjects: 246
Study 15598859 — intervention group
Group type: COMPARATOR
Intervention: No Deadline
Number of subjects: 246
Study 11281616 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation with guided imagery
Number of subjects: 20
Study 11281616 — intervention group
Group type: COMPARATOR
Intervention: Incremental exercise to fatigue
Number of subjects: 20
Study 11281616 — intervention group
Group type: COMPARATOR
Intervention: Cycling at 30% or 60% of maximum heart rate
Number of subjects: 20
Study 9154395 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Lamisil emulsion gel
Number of subjects: 83
Study 9154395 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 83
Study 7895384 — intervention group
Group type: COMPARATOR
Intervention: Intranasal sodium cromoglycate (single dose)
Number of subjects: 9
Study 7895384 — intervention group
Group type: COMPARATOR
Intervention: Intranasal sodium cromoglycate (3-week course)
Number of subjects: 9
Study 3266156 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100‐200 mg/day)
Number of subjects: 88
Study 3266156 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (50‐100 mg/day)
Number of subjects: 88
Study 3266156 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 88
Study 31139889 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein intake
Number of subjects: 79
Study 31139889 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein intake
Number of subjects: 79
Study 31139889 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat intake (high tertile)
Number of subjects: 79
Study 31139889 — intervention group
Group type: EXPERIMENTAL
Intervention: Total or relative protein intake, or ratio of animal to plant protein
Number of subjects: 79
Study 31888589 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed incentives
Number of subjects: 60
Study 31888589 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed incentives
Number of subjects: 60
Study 31888589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based incentives
Number of subjects: 60
Study 31888589 — intervention group
Group type: EXPERIMENTAL
Intervention: Public settings with incentives
Number of subjects: 60
Study 31888589 — intervention group
Group type: EXPERIMENTAL
Intervention: Low perceived prize values
Number of subjects: 60
Study 31888589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic motivation to test
Number of subjects: 60
Study 28708863 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 administration with therapeutic vaccination (ALVACHIV/Lipo-6T)
Number of subjects: 0
Study 28708863 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 administration
Number of subjects: 0
Study 25345664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional harm scenario
Number of subjects: 300
Study 25345664 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintentional harm scenario
Number of subjects: 300
Study 25345664 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranoia assessment
Number of subjects: 300
Study 25345664 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety assessment
Number of subjects: 300
Study 23922114 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 40 mg thrice weekly (initially), then reduced to 20 mg thrice weekly after nine patients due to safety concerns.
Number of subjects: 47
Study 20739577 — intervention group
Group type: EXPERIMENTAL
Intervention: Story-sharing group in their own language
Number of subjects: 157
Study 20739577 — intervention group
Group type: COMPARATOR
Intervention: Usual care self-management education (control)
Number of subjects: 157
Study 18501096 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with bevacizumab
Number of subjects: 260
Study 18501096 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin without bevacizumab (control group)
Number of subjects: 260
Study 17134516 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford Arthritis Self-Management Program (ASMP) and an arthritis self-management book
Number of subjects: 600
Study 17134516 — intervention group
Group type: COMPARATOR
Intervention: Control group (arthritis self-management book only)
Number of subjects: 600
Study 17134516 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford ASMP
Number of subjects: 600
Study 12796155 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micro g bid
Number of subjects: 2853
Study 12796155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2853
Study 11007224 — intervention group
Group type: EXPERIMENTAL
Intervention: Single rapid bolus of meperidine and midazolam
Number of subjects: 101
Study 11007224 — intervention group
Group type: COMPARATOR
Intervention: Titration of doses every 3 min until predefined levels of somnolence were achieved
Number of subjects: 101
Study 8985524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (25 mg/kg total, divided into 15 mg/kg initially and 10 mg/kg after 12 hours)
Number of subjects: 500
Study 8985524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine combined with an artemisinin derivative
Number of subjects: 500
Study 1476911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (calcium blocker)
Number of subjects: 144
Study 1476911 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (control)
Number of subjects: 144
Study 1476911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 144
Study 6731327 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 6731327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31326630 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with arthroplasty
Number of subjects: 253
Study 31326630 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with intervertebral cage
Number of subjects: 253
Study 31326630 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without intervertebral cage
Number of subjects: 253
Study 29187594 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma urate (100 µmol/L increase)
Number of subjects: 114979
Study 29187594 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined high plasma urate (100 µmol/L increase)
Number of subjects: 114979
Study 29187594 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma urate
Number of subjects: 114979
Study 26891879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 26891879 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 26891879 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel glutamate-modulating agents
Number of subjects: 0
Study 26891879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25490802 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood Alarm Systems (LASs)
Number of subjects: 0
Study 25490802 — intervention group
Group type: COMPARATOR
Intervention: Binary Alarm Systems (BASs)
Number of subjects: 0
Study 22527829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (total dose 2160 mg i.v.) + 0.45% saline (1 mL/kg/h over 24 h)
Number of subjects: 30
Study 22527829 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (total dose 4800 mg p.o.) + 0.45% saline (1 mL/kg/h over 24 h)
Number of subjects: 30
Study 22527829 — intervention group
Group type: COMPARATOR
Intervention: 0.45% saline alone
Number of subjects: 30
Study 20484838 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverages with apple polyphenols (600 mg)
Number of subjects: 124
Study 20484838 — intervention group
Group type: COMPARATOR
Intervention: Beverages without apple polyphenols (placebo)
Number of subjects: 124
Study 17115178 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (IE(A), 50% of MAV)
Number of subjects: 8
Study 17115178 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (IE(P))
Number of subjects: 8
Study 16140974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 2 years
Number of subjects: 500
Study 16140974 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 500
Study 12097660 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (100 mg Fe/d as ferrous sulfate) for 6 weeks
Number of subjects: 23
Study 12097660 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation (22 mg Zn/d as zinc gluconate) for 6 weeks
Number of subjects: 23
Study 10081531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.9 mg kg‐1 i.v.
Number of subjects: 52
Study 10081531 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 0.5 mg kg‐1 i.v.
Number of subjects: 52
Study 7593724 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide once daily (OD)
Number of subjects: 189
Study 7593724 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide three times daily (TDS)
Number of subjects: 189
Study 7593724 — intervention group
Group type: COMPARATOR
Intervention: Placebo (used for double-blind control)
Number of subjects: 189
Study 2407336 — intervention group
Group type: EXPERIMENTAL
Intervention: IF radiotherapy + MOPP chemotherapy
Number of subjects: 228
Study 2407336 — intervention group
Group type: COMPARATOR
Intervention: IF radiotherapy alone
Number of subjects: 228
Study 2407336 — intervention group
Group type: COMPARATOR
Intervention: EF radiotherapy
Number of subjects: 228
Study 2407336 — intervention group
Group type: EXPERIMENTAL
Intervention: IF radiotherapy + MOPP chemotherapy (CCSG and CALGB)
Number of subjects: 228
Study 6893563 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole
Number of subjects: 20
Study 6893563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31956660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod-liver oil
Number of subjects: 550
Study 31956660 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo, mineral oil)
Number of subjects: 550
Study 30369321 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care for OSA diagnosis and treatment
Number of subjects: 252
Study 30369321 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care for OSA diagnosis and treatment
Number of subjects: 252
Study 30369321 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 252
Study 30369321 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure use among patients with OSA
Number of subjects: 252
Study 30369321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients with best neurological symptom severity (National Institutes of Health Stroke Scale score, 0-1)
Number of subjects: 252
Study 26975818 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 36
Study 26975818 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 36
Study 24909563 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosis/stretch combinations
Number of subjects: 96
Study 24909563 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatments (1 or more)
Number of subjects: 96
Study 24909563 — intervention group
Group type: COMPARATOR
Intervention: Surgery for CTS
Number of subjects: 96
Study 22454332 — intervention group
Group type: EXPERIMENTAL
Intervention: Simon task
Number of subjects: 0
Study 22454332 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus-Response Compatibility (SRC) task
Number of subjects: 0
Study 19461562 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg/mL morphine with 0.2% ropivacaine
Number of subjects: 40
Study 19461562 — intervention group
Group type: COMPARATOR
Intervention: 25 mg/mL morphine with 0.2% ropivacaine
Number of subjects: 40
Study 17617283 — intervention group
Group type: COMPARATOR
Intervention: Moxonidine 0.2 mg once daily (M0.2)
Number of subjects: 99
Study 17617283 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 mg BID (M0.4)
Number of subjects: 99
Study 17617283 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 mg plus Irbesartan 150 mg (M0.2+1)
Number of subjects: 99
Study 15165654 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training intervention (manual plus five weekly group-based sessions)
Number of subjects: 60
Study 15165654 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training intervention
Number of subjects: 60
Study 15165654 — intervention group
Group type: COMPARATOR
Intervention: Control condition (one-page leaflet)
Number of subjects: 60
Study 12117747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (500 mg/m2)
Number of subjects: 10
Study 12117747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10088770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroids (3.75 mg of cortivazol in 1.5 ml)
Number of subjects: 98
Study 10088770 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint lavage and intraarticular corticosteroid
Number of subjects: 98
Study 10088770 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular placebo (1.5 ml of 0.9% normal saline)
Number of subjects: 98
Study 10088770 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint lavage and intraarticular placebo
Number of subjects: 98
Study 7491940 — intervention group
Group type: EXPERIMENTAL
Intervention: 56 mg arginine.kg‐1.day‐1 for 6 days
Number of subjects: 5
Study 7491940 — intervention group
Group type: EXPERIMENTAL
Intervention: 561 mg arginine.kg‐1.day‐1 for 6 days
Number of subjects: 5
Study 7491940 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation
Number of subjects: 5
Study 2110560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 54
Study 2110560 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 54
Study 2110560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 341733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-neomycin
Number of subjects: 0
Study 341733 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin-neomycin
Number of subjects: 0
Study 30620948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap‐assisted esophagogastroduodenoscopy (CA‐EGD)
Number of subjects: 171
Study 30620948 — intervention group
Group type: COMPARATOR
Intervention: Standard duodenoscopy
Number of subjects: 171
Study 30620948 — intervention group
Group type: EXPERIMENTAL
Intervention: CA‐EGD
Number of subjects: 171
Study 28244271 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-delivered intervention promoting first relationships (PFR), n=19
Number of subjects: 33
Study 28244271 — intervention group
Group type: COMPARATOR
Intervention: Ongoing assessment without intervention, n=14
Number of subjects: 33
Study 26390746 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 163
Study 26390746 — intervention group
Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 163
Study 23365148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic formulations (SGCG and SGC)
Number of subjects: 440
Study 23365148 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine (2 g daily)
Number of subjects: 440
Study 23365148 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg daily)
Number of subjects: 440
Study 22168295 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored care management intervention
Number of subjects: 30
Study 22168295 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 30
Study 19127197 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EG)
Number of subjects: 65
Study 16912480 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency cranial electrostimulation (CES) for 30 min a day, during 6 weeks
Number of subjects: 20
Study 16912480 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control) for 30 min a day, during 6 weeks
Number of subjects: 20